Delcath Systems (NASDAQ:DCTH – Get Rating) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued on Friday.
Separately, HC Wainwright dropped their target price on shares of Delcath Systems from $19.00 to $17.00 and set a “buy” rating on the stock in a report on Tuesday, March 28th.
Delcath Systems Price Performance
Shares of Delcath Systems stock opened at $7.55 on Friday. Delcath Systems has a 1 year low of $2.34 and a 1 year high of $7.67. The firm’s 50-day moving average is $5.84 and its two-hundred day moving average is $4.52. The stock has a market cap of $80.19 million, a price-to-earnings ratio of -2.02 and a beta of 0.86.
In other news, CEO Gerard J. Michel purchased 19,646 shares of the stock in a transaction dated Wednesday, March 29th. The shares were acquired at an average cost of $4.84 per share, for a total transaction of $95,086.64. Following the acquisition, the chief executive officer now owns 197,235 shares of the company’s stock, valued at $954,617.40. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 16.76% of the company’s stock.
Institutional Trading of Delcath Systems
Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Delcath Systems by 5.7% in the 1st quarter. Vanguard Group Inc. now owns 360,900 shares of the company’s stock valued at $2,309,000 after purchasing an additional 19,605 shares during the last quarter. Cibc World Market Inc. raised its position in shares of Delcath Systems by 4.0% in the 1st quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock valued at $568,000 after purchasing an additional 3,432 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Delcath Systems by 4.8% in the 1st quarter. Geode Capital Management LLC now owns 62,733 shares of the company’s stock valued at $361,000 after purchasing an additional 2,851 shares during the last quarter. BlackRock Inc. raised its position in shares of Delcath Systems by 22.3% in the 1st quarter. BlackRock Inc. now owns 16,632 shares of the company’s stock valued at $96,000 after purchasing an additional 3,032 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Delcath Systems in the 1st quarter valued at approximately $75,000. 25.66% of the stock is currently owned by institutional investors.
Delcath Systems Company Profile
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
- Get a free copy of the StockNews.com research report on Delcath Systems (DCTH)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.